Pharma patents Archives

Green Cross Crosses court’s bridge to win appeal

The Madras High Court has revoked the refusal of Green Cross’ patent application for a Hepatitis B immunoglobulin agent, citing errors in the Controller’s analysis. The court has remanded the matter to the patent office for a fresh examination, ordering a review of the claims within four months. Continue Reading Green Cross Crosses court’s bridge to win appeal

August 15, 2024 BananaIP Reporter Case Reviews, Intellectual Property, Patents 0Comment 273Views 0Like

ShareFacebook

A Patently Generic Win

This post was first published on April 23, 2012. In a landmark decision on a generic drug-maker’s ability to introduce a generic drug for uses not indicated on the branded product’s label, the US Supreme Court ruled in favour of Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries, in its patent litigation against Novo Nordisk over Caraco’s generic version of Prandin, repaglinide tablets, a blood glucose lowering drug. The drug in question, Prandin, generically known as repaglinide, is used…

August 2, 2019 BananaIP Reporter Intellectual Property, Patents 0Comment 769Views 0Like

ShareFacebook

Restricting ‘Pay-for-Delay’ Agreements

This post was first published on 6th August, 2014. A total of more than 420 million Euros was imposed recently as fine by the European Competition Commission on five major Pharma companies for entering into ‘Pay-for-delay’ agreements with Generic companies. These fines and related measures were imposed to restrict the drug majors from entering into these non-competitive kind of deals to maximize their commercial gains. Of the five, the drug maker, Servier has been fined 331 million Euros for the anti-hypertensive…

July 26, 2019 BananaIP Reporter Intellectual Property, Patents 0Comment 706Views 0Like

ShareFacebook

Indian Patent Statistics, Interesting Inventions, WIPO – India Summer School, NATCO Pharma patent settlement and more

“Indian Patent Statistics, Interesting Inventions, Industrial Designs Statistics, BananaIP completes 15 years, WIPO – India Summer School on IP to begin in June, NATCO Pharma settles infringement dispute with Onyx Therapeutics, South Korea to host this year’s IP5 roundtable and more patent news” presented by the Patent attorneys and experts of BananaIP Counsels, India’s leading Patent Firm. Quote of the Week “Patent knowledge cannot promote scientific progress unless it is accessible.” - Dr. Kalyan C. Kankanala, BananaIP Counsels Indian Patent…

June 3, 2019 BananaIP Reporter Intellectual Property, Patents 0Comment 960Views 0Like

ShareFacebook

Patent Suit over Viagra

This post was first published on June 7, 2011. Pfizer Inc. filed a suit against Watson Laboratories, on June 1, 2011 in the United States District Court for the Southern District of New York seeking to prevent Watson from commercializing sildenafil citrate tablets prior to the expiration of Pfizer’s Viagra. Watson's sildenafil citrate tablets are a generic version of Pfizer Inc.'s Viagra, which is indicated for the treatment of erectile dysfunction (ED). Sildenafil citrate enhances the effect of nitric oxide, which…

February 13, 2019 BananaIP Reporter Intellectual Property, Patents 0Comment 932Views 0Like

ShareFacebook

Generication of Public Interest

This post was first published on 18th February, 2011. Public Interest today is a potent weapon of generic companies to safeguard their interests in the changing patent landscape in India. India's membership to WTO required implementation of the product patent regime for drugs by 2005 and implementation of the obligation was opposed by generic companies in the name of public interest. It was argued that the introduction of such a regime would impede access to medicines and health…

January 30, 2019 BananaIP Reporter Intellectual Property, Patents 0Comment 924Views 0Like

ShareFacebook

Abbott’s HIV Drug Patent “Not an Invention”

This post was first published on 18th January, 2011. In a recent case, reported here by Sandeep, the patent office denied patent grant to Abbott’s HIV drug application (application No:339/MUMNP/2006, WO2005/039551), stating that the subject matter did not constitute an invention. Abbott’s application was rejected as a result of the pre grant oppositions filed by Initiative for Medicines, Access & Knowledge’ (I-MAK), Cipla (Mumbai), Matrix Laboratories (Secunderabad) and Okasa Pharmaceuticals (Mumbai). The complete specification of Abbott’s application was entitled “SOLID PHARMACEUTICAL DOSAGE…

January 24, 2019 BananaIP Reporter Intellectual Property, Patents 0Comment 857Views 0Like

ShareFacebook

Patent Law News Update

Interesting Patents, Amazon’s parachute-dropping drone, Facebook - electronic payment service, Recent Patent Grants, Glenmark obtains US FDA approval, Pharma Patents, Whirlpool Patent Infringement, Stupid Designs, Patent Search, Patent Tip and more, presented by the Patent attorneys and experts of BananaIP Counsels, India’s Premier New Age IP Firm. Patent Quote of the week “Abraham Lincoln said, Patents Add Fuel to the Fire of Genius. What the great man did not say is that Too Much Fuel Can Burn the Genius” ― Dr. Kalyan C.…

June 5, 2017 BananaIP Reporter Intellectual Property, Patents 0Comment 749Views 0Like

ShareFacebook

The image is of medicines as the post is about pharma patents and access to medicines and a conference held on the topic. To read click here.

‘Affordability, Availability, Accessibility of medicines’

The Centre for Intellectual Property Rights Research and Advocacy, headed by Professor T. Ramakrishna (Chair professor of IP at NLSIU), and the MHRD Chair on IPR of National Law School of India University, Bangalore in association with the National Pharmaceutical Pricing Authority, New Delhi organized a one day national conference on ‘Affordability, Availability, Accessibility of medicines and IPR’ on the 5th of January 2016. The main objective of the conference was to provide a platform to the government representatives, stakeholders…

January 8, 2016 BananaIP Reporter Intellectual Property, Patents 0Comment 1000Views 0Like

ShareFacebook

The image says Pharma Patents and Drug Prices, as the post contains a presentation on the same. Click to read more.

Pharma Patents and Drug Prices- A Presentation by Dr. Kalyan C. Kankanala at NLSIU, Bangalore

The following presentation titled ‘Pharma Patents and Drug Prices’ was delivered by Dr. Kalyan C. Kankanala (Managing Partner, BananaIP Counsels, Bangalore) on 5th January, 2016 at the conference on “Affordability, Accessibility and Availability of Medicine and IPR” at National Law School of India University. Organized through the Centre for Intellectual Property Rights Research and Advocacy and MHRD Chair on Intellectual Property Rights, the conference was held at the International Training Centre, NLSIU, Bengaluru. The following topics were covered as a…

January 5, 2016 BananaIP Reporter Patents 0Comment 720Views 0Like

ShareFacebook

Celebrating 20 Years of IP Excellence

Green Cross Crosses court’s bridge to win appeal

A Patently Generic Win

Restricting ‘Pay-for-Delay’ Agreements

Patent Suit over Viagra

Generication of Public Interest

Abbott’s HIV Drug Patent “Not an Invention”

Patent Law News Update

‘Affordability, Availability, Accessibility of medicines’

Pharma Patents and Drug Prices- A Presentation by Dr. Kalyan C. Kankanala at NLSIU, Bangalore

Connect with Us

BananaIP has been acknowledged as a women-owned enterprise, certified by WEConnect International.

Connect with us